Abbott Laboratories $ABT Shares Sold by Banco Santander S.A.

Banco Santander S.A. reduced its holdings in Abbott Laboratories (NYSE:ABT) by 12.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,567 shares of the healthcare product maker’s stock after selling 5,008 shares during the period. Banco Santander S.A.’s holdings in Abbott Laboratories were worth $4,630,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories in the third quarter valued at about $31,000. Anfield Capital Management LLC increased its stake in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares in the last quarter. Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth about $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories in the 3rd quarter valued at about $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $116.17 on Friday. The company has a current ratio of 1.58, a quick ratio of 1.24 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $117.34 and a 200 day moving average price of $125.30. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23. The stock has a market cap of $201.87 billion, a P/E ratio of 31.23, a PEG ratio of 1.85 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s payout ratio is currently 67.74%.

Analysts Set New Price Targets

ABT has been the subject of several research reports. Sanford C. Bernstein cut their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. BTIG Research reduced their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Evercore lowered their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the purchase, the director directly owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.